Versiti Blood Center of Wisconsin Trials

Versiti Blood Center of Wisconsin	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Malec, Lynn

The Atlanta Study, NCT04030052: Emicizumab PUPs and Nuwiq ITI Study

Withdrawn

Nuwiq (low dose protocol), Simoctocog alfa, HEMLIBRA, Emicizumab, ACE910, and RO5534262, Nuwiq (Atlanta protocol)

Emory University, Genentech, Inc.

Hemophilia A

01/23

AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting

emicizumab, Hemlibra (R)

University of Washington, Genentech, Inc.

Acquired Hemophilia A

07/25

12/25

NCT04055051: ATHN 11: Liver Transplantation Outcomes Study

Completed

N/A

American Thrombosis and Hemostasis Network, BioMarin Pharmaceutical

Hemophilia A and B, Liver Transplantation

12/22

ATHN 9, NCT03853486: Severe VWD Natural History Study

Active, not recruiting

N/A

108

American Thrombosis and Hemostasis Network, Takeda

Von Willebrand Diseases

12/24

01/25

ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting

N/A

3000

American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S

Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease

06/35

12/35

Treml, Angela

NCT05629338: Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

Enrolling by invitation

Autologous Spray Dried Plasma, FrontlineODP Unit, Frontline On Demand Plasma Unit

Velico Medical

Coagulopathy, Hemorrhage

05/25

Treml, Anglea